Steven Gannon - 14 May 2025 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: Director
Signature: /s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol: XENE
Transactions as of: 14 May 2025
Net transactions value: +$64,660
Form type: 4
Filing time: 16 May 2025, 17:59:44 UTC
Previous filing: 05 Jun 2024
Next filing: 06 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
GANNON STEVEN	Director	3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA	/s/ Nathaniel Adams, Attorney-in-fact	16 May 2025	0001643085

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XENE	Common Shares	Options Exercise	$64,660	+5,144	+257%	$12.57	7,144	14 May 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XENE	Stock Option (Right to Buy)	Options Exercise	$0	-5,144	-100%	$0.000000	0	14 May 2025	Common Shares	5,144	$12.57	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option are fully vested and exercisable.